
RPHM
Healthcare · Biotechnology · $60.8M market cap
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2024
EPS trend, 90 days to now · 0.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Aug 13, 2024 | Before the open | -0.10 | -0.16 | -60.0% |
| May 7, 2024 | Before the open | -0.44 | -0.25 | +43.2% |
| Mar 28, 2024 | Before the open | -0.58 | -0.71 | -22.4% |
| Nov 13, 2023 | Before the open | -0.57 | -0.57 | 0.0% |
| Aug 10, 2023 | Before the open | -0.52 | -0.65 | -25.0% |
| May 11, 2023 | Before the open | -0.60 | -0.60 | 0.0% |
| Mar 27, 2023 | Before the open | -0.60 | -0.56 | +6.7% |
| Nov 8, 2022 | Before the open | -0.57 | -0.53 | +7.0% |
| Aug 9, 2022 | Before the open | -0.58 | -0.50 | +13.8% |
| May 10, 2022 | After the close | -0.54 | -0.53 | +1.9% |
| Mar 23, 2022 | After the close | -0.57 | -0.43 | +24.6% |
| Nov 11, 2021 | After the close | -0.47 | -0.52 | -10.6% |
| Aug 11, 2021 | Before the open | -0.38 | -0.43 |
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary…
| -13.2% |
| May 20, 2021 | Before the open | -0.38 | -3.48 | -815.8% |
| Mar 19, 2021 | After the close | 0.00 | -0.26 | — |